EGFR and neoplasm: Together these EVs delivered let-7a to EGFR expressing xenograft breast cancer cells in RAG2−/− mice, eliciting a significant (P < 0.05) ~60% reduction in tumour size following weekly administration of GE11+, let-7a+ EVs for four weeks [206].